Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Ben George

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9667-9833; OpenAlex author ID A5010681962, A5122672590. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
0
Labs led
0
Collaborators
76
Papers, trials and grants by year

2024: 1 paper · 2025: 2 papers · 2026: 5 papers

Papers 8

  1. Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial. Co-author DOI 10.1038/s41591-026-04734-7↗
  2. Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenoca… Co-author DOI 10.1158/0008-5472.can-25-0018↗
  3. Spatial Configuration of Pancreatic Cancer Is Associated with Disease Recurrence after Neoadjuvant Therapy and Curative-Intent Resection. Co-author DOI 10.1158/1078-0432.ccr-25-4968↗
  4. Key Considerations for Targeting KRAS in Pancreatic Cancer: Potential Impact on the Treatment Paradigm. Co-author DOI 10.2147/dddt.s559325↗
  5. Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinom… Co-author DOI 10.3390/cancers18030507↗
  6. Patterns of Locoregional Pancreatic Cancer Recurrence After Total Neoadjuvant Therapy and Implications on Optimal Neoadjuvant Radiation Treatment Volumes. Co-author DOI 10.1016/j.prro.2024.07.001↗
  7. A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borderline Resectable Pancreatic Adenocarcino… Co-author DOI 10.1158/1078-0432.ccr-24-3403↗
  8. Chemotherapy-free treatment targeting fusions and driver mutations in KRAS wild-type pancreatic ductal adenocarcinoma, a case series. Co-author DOI 10.1177/17588359241253113↗

Closest collaborators

The 25 strongest of 76 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. William Adrian Hall · 3 shared papers, 2024–2026 · strength 0.59
  2. Beth E. Erickson · 3 shared papers, 2024–2026 · strength 0.59
  3. Douglas B. Evans · 3 shared papers, 2024–2026 · strength 0.59
  4. Susan Tsai · 3 shared papers, 2024–2026 · strength 0.59
  5. Kathleen K. Christians · 3 shared papers, 2024–2026 · strength 0.59
  6. Mandana Kamgar · 3 shared papers, 2024–2026 · strength 0.59
  7. Tanios Bekaii‐Saab · 2 shared papers, 2026 · strength 0.55
  8. Andrew Eugene Hendifar · 2 shared papers, 2026 · strength 0.42
  9. Mohammed Aldakkak · 2 shared papers, 2025–2026 · strength 0.41
  10. Thomas B. McFall · 2 shared papers, 2024–2026 · strength 0.38
  11. Razelle Kurzrock · 2 shared papers, 2024–2026 · strength 0.38
  12. Callisia Nathelee Clarke · 2 shared papers, 2024–2025 · strength 0.38
  13. Mitesh J. Borad · 1 shared paper, 2026 · strength 0.36
  14. Mohamad Bassam Sonbol · 1 shared paper, 2026 · strength 0.36
  15. Cody R. Eslinger · 1 shared paper, 2026 · strength 0.36
  16. Hani M. Babiker · 1 shared paper, 2026 · strength 0.36
  17. Martin C. Whittle · 1 shared paper, 2026 · strength 0.23
  18. Christopher Hartley · 1 shared paper, 2026 · strength 0.23
  19. Khalid Jazieh · 1 shared paper, 2026 · strength 0.23
  20. Luis Humberto Cisneros · 1 shared paper, 2026 · strength 0.23
  21. Andrew L. Coveler · 1 shared paper, 2026 · strength 0.23
  22. Sita Kugel · 1 shared paper, 2026 · strength 0.23
  23. Cornelius A. Thiels · 1 shared paper, 2026 · strength 0.23
  24. Tomislav Dragovich · 1 shared paper, 2026 · strength 0.23
  25. Mark Joseph Truty · 1 shared paper, 2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.